PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase I drugs for Peripheral T-Cell Lymphomas (PTCL) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PA-317’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PA-317 overview

PA-317 therapy is under development for the treatment of relapsed and refractory CD7 positive acute T-lymphoblastic leukemia and lymphoma, extramedullary NK and T-cell lymphoma, peripheral T-cell lymphoma, vascular immunoblastic T-cell lymphoma, intestinal disease associated T-cell lymphomas, anaplastic large cell lymphoma, T-cell lymphoblastic leukemia, acute lymphocytic leukemia, lymphoblastic lymphoma, relapsed/refractory acute myeloid leukemia and T-cell lymphomas. The therapeutic candidate comprises of autologous, T cells genetically manipulated to express chimeric antigen receptor (CAR) targeting cells expressing CD7 antigen. The therapeutic candidate administered through intravenous route.

PersonGen BioTherapeutics (Suzhou) overview

PersonGen BioTherapeutics (Suzhou) (PersonGen) is a biotechnology company focused on developing CAR-related therapies, analytical antibodies, novel CAR-T therapeutics, and allogeneic cellular therapies. PersonGen is headquartered in Suzhou, Jiangsu, China.

For a complete picture of PA-317’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.